Martin Sadowski is a Neurology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
145 E 32nd St
New York, NY 100166055
Telephone
212-263-2152Provider last certified this registry record 26 Mar 2021.
Clinical trials
- Cognitive Detection of Preclinical AD: Validation Using Biomarkers
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20253 payments
- Biogen, Inc.Program year20251 payment
- Eisai Inc.Program year202417 payments$16,671openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Cholinesterase Inhibitor42.6%Galantamine Er58%Rivastigmine31%Donepezil Hcl10%Part D<11 patientsN-methyl-D-aspartate Receptor Antagonist38.2%Memantine Hcl75%Memantine Hcl Er25%Part D≥63 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
10 NIH research awards on record, funded 2002–2026 per NIH RePORTER. The latest:
- Off-the-shelf CAR-Engineered Macrophage Therapy for Alzheimer’s Disease
New York University School of Medicine
FY2026$805,720R61AG090384 - Role of Microglia in Neurodegeneration -Effect of ApoE
New York University School of Medicine
FY2026$680,533R01AG075840 - Off-the-shelf CAR-Engineered Macrophage Therapy for Alzheimer’s Disease
New York University School of Medicine
FY2025$810,596R61AG090384
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”